$0.34 Earnings Per Share Expected for Boston Scientific Corporation (BSX) This Quarter

Wall Street analysts expect Boston Scientific Corporation (NYSE:BSX) to announce $0.34 earnings per share for the current fiscal quarter, according to Zacks. Ten analysts have issued estimates for Boston Scientific’s earnings, with the lowest EPS estimate coming in at $0.31 and the highest estimate coming in at $0.35. Boston Scientific reported earnings per share of $0.30 during the same quarter last year, which indicates a positive year-over-year growth rate of 13.3%. The company is scheduled to report its next earnings report on Thursday, February 1st.

According to Zacks, analysts expect that Boston Scientific will report full year earnings of $1.25 per share for the current year, with EPS estimates ranging from $1.23 to $1.26. For the next financial year, analysts expect that the firm will report earnings of $1.38 per share, with EPS estimates ranging from $1.34 to $1.43. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Boston Scientific.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.31. The firm had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.27 earnings per share.

Several analysts have weighed in on the stock. Oppenheimer reiterated a “hold” rating on shares of Boston Scientific in a research note on Wednesday, August 9th. BMO Capital Markets reiterated a “buy” rating and set a $31.00 target price on shares of Boston Scientific in a research note on Wednesday, November 29th. Zacks Investment Research lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Canaccord Genuity lowered their target price on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, November 29th. Finally, BidaskClub upgraded shares of Boston Scientific from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. One research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $30.97.

Boston Scientific (NYSE BSX) traded down $0.20 on Monday, reaching $25.04. 9,674,608 shares of the company traded hands, compared to its average volume of 6,979,998. The firm has a market capitalization of $34,247.51, a PE ratio of 20.44, a PEG ratio of 1.92 and a beta of 0.96. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. Boston Scientific has a 1 year low of $20.37 and a 1 year high of $29.93.

In other news, EVP Timothy A. Pratt sold 10,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $26.04, for a total transaction of $260,400.00. Following the completion of the transaction, the executive vice president now owns 154,681 shares in the company, valued at $4,027,893.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Timothy A. Pratt sold 11,061 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $29.24, for a total transaction of $323,423.64. Following the transaction, the executive vice president now owns 174,681 shares of the company’s stock, valued at approximately $5,107,672.44. The disclosure for this sale can be found here. Insiders have sold 424,698 shares of company stock valued at $12,273,553 in the last 90 days. Insiders own 0.74% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in BSX. Janus Henderson Group PLC grew its position in Boston Scientific by 22,491.6% in the 2nd quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock valued at $1,077,270,000 after buying an additional 38,690,577 shares in the last quarter. Jennison Associates LLC grew its position in Boston Scientific by 405.3% in the 2nd quarter. Jennison Associates LLC now owns 10,639,290 shares of the medical equipment provider’s stock valued at $294,921,000 after buying an additional 8,533,655 shares in the last quarter. BlackRock Inc. grew its position in Boston Scientific by 4.6% in the 2nd quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock valued at $2,777,113,000 after buying an additional 4,439,966 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its position in Boston Scientific by 35,016.2% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock valued at $84,337,000 after buying an additional 3,033,800 shares in the last quarter. Finally, Prudential Financial Inc. grew its position in Boston Scientific by 149.1% in the 3rd quarter. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider’s stock valued at $138,928,000 after buying an additional 2,850,630 shares in the last quarter. Hedge funds and other institutional investors own 90.57% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.thestockobserver.com/2017/12/07/0-34-earnings-per-share-expected-for-boston-scientific-corporation-bsx-this-quarter.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Get a free copy of the Zacks research report on Boston Scientific (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply